Watchlist for December 13, 2007

See one of the recent 'Chart Reading' posts for some potential swing candidates.

Potential day trades:

(From Briefing.com)

Gapping Down

In reaction to weak earnings/guidance: ASYS -17.8% SCSS -15.7% (Discloses in its 8-K that sales profits will fall short of previous guidance), COST -6.3%, VITL -6.2%, CKR -4.7%, LEH -2.1%, CPII -1.3%, NSPH -1.1%... Other news: NBIX -46.3% (receives approvable letter for indiplon capsules with additional safety and efficacy data required by FDA), BIIB -27.5% (completes review of strategic alternatives; did not receive any definitive offers), ADPI -23.3% (provides update on lawsuit -- jury found PDHC or ADPI liable for breach of the service agreement and awarded compensatory damages of $9.4 mln; this follows yesterday's 27% sell-off in the stock), WSTL -8.5% (receives notice of SEC investigation), SCA -8.3% (Fitch reviewing its AAA ratings), ELN -6.2% (in response to BIIB announcement, co reaffirms commitment to Tysabri), ACH -5.3% (still checking), LIHR -5.1% (cuts production forecast by 7% to 700k oz - DJ), POT -4.3% (files for a $2 bln debt securities shelf offering), BIDZ -4.3% (presented at Wedbush conference after the close, issues guidance), QCOM -2.4% (judge issues ruling saying NOK does not infringe QCOM in patent infringement complaint, also downgraded to Neutral at Merrill), MT -1.3% (to increase stake in China Oriental), AGU -1.0% (prices secondary offering at $58)... Analyst downgrades: RIO -3.6% (hearing downgraded to Neutral at tier-1 firm), WM -3.1% (downgraded to Sell at BofA), COF -2.6% (downgraded to Hold at Jefferies), RHT -2.2% (downgraded to Sell at BofA), PMCS -1.4% (initiated with Sell at BofA), CME -1.0% (hearing removed from Conviction Buy list at tier-1 firm).

Gapping Up

In reaction to strong earnings/guidance: MATK +13.2%, ADCT +8.7% (also upgraded to Buy at Merriman), JOSB +6.6%, GXDX +6.2% (also initiated with Outperform at Cowen), KMGB +3.6%, HAYN +3.3%, CIEN +2.6%, MDZ +1.1%, LII +1.1%, HON +1.0%... M&A news: MGI +27.5% (to be acquired by EEFT for $20/share)... Other news: RIGL +75.0% (demonstrates significant improvement in rheumatoid arthritis in Phase 2 clinical study), SVNT +45.2% (meets pre-specified primary efficacy endpoint in two replicate Phase 3 studies ), DEPO +21.2% (says Court grants motion for Summary Judgement of patent infringement against IVAX), DOW +7.8% (DOW and Petrochemical Industries announce plans to form a 50/50 joint venture in global petrochemicals co) PSPT +7.5% (Board rejects IPVG and AO Capital Partners unsolicited proposal of $15/share), VNDA +4.0% (presents Phase 3 iloperidone efficacy data), XMSR +3.7% (members of US House Antitrust Panel express concern over merger - Reuters), UMBF +3.2% (will replace EDO in S&P SmallCap 600), RATE +2.4% (initiated with Neutral at BofA), CPSL +2.0% (announces that it has new independent registered public accounting firm), FTK +1.6% (announces has filed an application to list its common stock on the NYSE), MON +1.2% (Cramer makes positive comments on MadMoney), SIGM +1.2% (Cramer makes positive comments on MadMoney), JCOM +1.2% (acquires RapidFax business from Easylink Services), FRT +1.1% (will replace LYO in S&P MidCap 400), PLCE +1.1% (names Richard Paradise Chief Financial Officer), HNR +1.0% (announces it has executed a sale and purchase agreement to acquire a 50% operated interest in the Dussafu Marin Exploration Production Sharing Contract)... Analyst upgrades: ESLR +4.1% (initiated with Buy at UBS), JRCC +3.9% (initiated with Buy at UBS), RATE +2.4% (initiated with Neutral and $55 tgt at BofA), CYNO +2.2% (upgraded to Buy at Citigroup), GA +2.0% (initiated with Buy at UBS), FSLR +1.4% (initiated with Buy and $350 tgt at UBS), SPWR +1.0% (initiated with Buy at UBS, Cramer makes positive comments on MadMoney).

Disclaimer & How I use this list